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Abstract Susceptibility to Wilson’s disease (WD) and its
clinical manifestations are thought to be affected by genetic
factors, including polymorphisms. The role of brain-derived
neurotrophic factor (BDNF) in the pathogenesis of neurode-
generative diseases is now widely discussed. The aim of the
present study was to evaluate the frequency of the BDNF
Val66Met (G-196A) and C-270T polymorphisms in WD
patients and in healthy controls, and to determine the role
of these polymorphisms in the clinical characteristics of
WD. We found that the BDNF Val/Val (−196 G/G) and
−270 C/T genotypes occurred more frequently in WD pa-
tients than in healthy controls (66 % versus 45.5 %, p=0.
0001, and 14 % versus 6 %, p=0.018, respectively).
Similarly, symptomatic patients carried the BDNF Val/Val
genotype more often than presymptomatic patients (75 %
versus 53 %, p=0.0097). No association was detected be-
tween any of the determined polymorphisms and the dom-
inant form of the disease or the age of onset for WD.
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Introduction
Wilson’s disease (WD) is a rare inherited disease of copper
metabolism that can lead to the accumulation of copper and
damage to several organs. The main symptoms are liver
failure and neuropsychiatric manifestations; symptomatolo-
gy and age at symptom onset are thought to vary greatly
among patients. Genetic variability, including gene muta-
tions and polymorphisms, may underlie this variability.
Mutation of ATP7B has been shown to affect disease man-
ifestation (Gromadzka et al. 2006), but polymorphisms in,
for example, the methyltetrahydrofolate reductase gene
(Gromadzka et al . 2011) , some cytokine genes
(Gromadzka et al. 2011), and the apolipoprotein gene
(Schiefermeier et al. 2000; Litwin et al. 2012) may be
essential for the clinical characteristics of WD. Other genes,
such as those encoding antioxidant-1, copper metabolism
gene MURR1 domain-containing protein, and X-linked in-
hibitor of apoptosis have also been investigated, but with
conflicting results (reviewed by Litwin et al. 2013).
Although WD is recognized as a neurodegenerative dis-
ease, previous studies of the pathogenesis of some neurode-
generative disorders revealed increased expression of pro-
inflammatory cytokines in the brains of experimental animals
and of patients. The inflammatory process is considered to be
one step in neuronal degeneration (Frank-Cannon et al. 2009).
The role of neurotrophins, including polymorphisms in brain-
derived neurotrophic factor (BDNF), is now discussed widely
with regard to susceptibility to neurodegeneration and to the
courses of various neurological diseases, such as Parkinson’s
disease (Gao et al. 2010), Alzheimer’s disease (Laske et al.
2006), and Huntington’s disease (Albrech et al. 2005;
Koshikawa et al. 2006). The effects of polymorphisms have
also been explored in multiple sclerosis (Mirowska-Guzel et al.
2008; Mero et al. 2012), a disease in which neurodegeneration
is thought to be secondary to autoimmunity.
The best-known BDNF polymorphism is G-196A, which
results in a change of valine to methionine at codon 66
(Val66Met). The Met allele is associated with impaired intra-
cellular trafficking and activity-dependent secretion of BDNF
in neurons (Egan et al. 2003; Chen et al. 2004). A second
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polymorphism, C-270T, occurs in the 5′-noncoding region of
BDNF; functionality of this polymorphism is suspected, but
has not been fully elucidated (Szczepankiewicz et al. 2005).
Although at present the BDNF C-270T polymorphism is not
known to cause changes in BDNF, the T allele is thought to
affect the translation efficacy of BDNF (Kunugi et al. 2001).
No data are currently available on the impact of BDNF genetic
variants on WD susceptibility and symptomatology.
The aim of the present study was to compare the frequency
of the BDNFVal66Met (G-196A) and C-270T polymorphisms
in WD patients and in healthy controls, and to determine the
role of these polymorphisms in the clinical characteristics of
WD in terms of the clinically dominant form, its symptomatol-
ogy, and age at onset in a large patient population.
Materials and methods
Patients and controls
We studied 414 patients diagnosed withWD at the Institute of
Psychiatry and Neurology in Warsaw, Poland, between 1970
and 2010. A total of 145 healthy volunteers served as a control
group. This study was approved by the local ethics committee,
and informed consent was provided by all subjects included in
the study. Patient diagnoses were based on clinical symptoms,
abnormal copper metabolism (decreased serum ceruloplasmin
and serum copper, increased 24-h urinary copper excretion),
and the presence of the Kayser-Fleischer ring; many diagnoses
were confirmed by genetic examination (Gromadzka et al.
2011). Clinical and family data, as well as physical, neurolog-
ical, laboratory, brain magnetic resonance, and liver examina-
tion data were collected if available.
Patients with WD were divided into two groups according
to the presence of clinical symptoms: presymptomatic and
symptomatic. The presymptomatic group consisted of patients
without clinical symptoms or signs of WD (usually siblings of
the index case), and these patients were only included in the
overall BDNF polymorphism distribution. The symptomatic
group consisted of patients with clinical signs of WD at onset.
The clinical form of WD was established based on the
presence and intensity of individual signs of WD at diagno-
sis. In symptomatic patients, a predominant symptoms scor-
ing system at diagnosis was used as described in previous
studies (Merle et al. 2007; Litwin et al. 2012). The assess-
ment of hepatic signs and symptoms was based on a detailed
questionnaire that included data on fatigue, weight loss, leg
edema, jaundice, abdominal swelling, hematemesis,
hemorrhaging, fulminant liver failure, and laboratory exam-
inations (e.g., ultrasound, liver and spleen assessment, and
measurement of aminotransferases, bilirubin, international
normalized ratio for blood coagulation, and albumin) avail-
able from medical history and records. The evaluation of
neuropsychiatric symptoms and signs was also based on a
detailed questionnaire and included data on salivation, dys-
phagia, speech, writing and gait disturbances, involuntary
movements, adynamia, epileptic seizures, mood disorders,
anxiety, and cognitive impairment. Neurological symptoms
at diagnosis were classified (i.e., rigidity-tremor, tremor,
dystonic, rigidity) by a system used in our department since
1960 and described by Marsden (1987). Age at the onset of
WD symptoms and at diagnosis was assessed based on
patient history, symptoms and signs of WD, and/or available
medical documentation, as well as the results of clinical and
laboratory investigations.
BDNF polymorphisms
Genomic DNA was isolated using Tri-Reagent (Sigma,
Poland). BDNF Val66Met (G-196A) and C-270T
genotyping was performed by polymerase chain reaction
restriction fragment length polymorphism analysis as de-
scribed previously (Riemenschneider et al. 2002; Neves-
Pereira et al. 2002). ATP7B genotyping was performed by
polymerase chain reaction restriction fragment length poly-
morphism analysis and/or direct ATP7B gene sequencing as
described previously (Gromadzka et al. 2006).
Statistical analysis
Statistical analyses were carried out with STATISTICA PL
(version 10.0) provided by StatSoft® (2012, Poland).
Genotype and allele frequencies were compared with the
chi-squared test. The Bonferroni correction for multiple
comparisons was used as needed. The Mann–Whitney U
test was used for comparisons of two independent groups.
Results of multiple logistic regression are expressed as an
adjusted odds ratio (OR) and a 95 % confidence interval
(95 % CI). Significance was set at p≤0.05.
Results
Patient demographics and clinical characteristics
A total of 414 patients (220 women and 194 men) were
enrolled in the study (Table 1). The control group consisted
of 145 healthy sex- (83 females and 62 males) and age-
(mean±standard deviation, 40.09±10.19 years) matched
volunteers.
BDNF Val66Met and C-270T polymorphisms and WD
susceptibility
No significant differences were found in the BDNF allele
and genotype distributions between male and female
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patients and healthy volunteers (data not shown). However,
significant differences were detected in the distributions of
Val66Met and C-270T alleles and genotypes between WD
patients and healthy volunteers, even when Bonferroni cor-
rection for multiple comparisons was applied. None of the
control subjects carried the BDNF Met/Met genotype; thus,
in the patient group the Met/Met genotype was combined
with the Val/Met genotype for statistical purposes (Table 2).
In logistic regression analysis, the BDNF Val/Val and −270
C/T genotypes were more frequent in patients withWD than in
controls (p=0.0001, OR 2.26, 95 % CI 1.54–3.33, and p=0.
046, OR 2.12, 95 % CI 1.01–4.45, respectively). BDNF
Val/Val and −270 C/T occurred together in 10 % of WD
patients and in 4 % of healthy controls (p=0.001, OR 1.69,
95 % CI 1.53–1.86).
BDNF polymorphisms and course of WD
No differences were found in the distributions of the BDNF
Val66Met and −270 C/T genotypes between patients with
predominant neurological-psychiatric disease and patients
with the hepatic form of the disease at diagnosis. The BDNF
Val/Val genotype was detected in 68 % of WD patients with a
neuropsychiatric form of the disease and in 68 % of patients
with the dominant hepatic form. The BDNF −270 C/C geno-
type was detected in 84 % and 85 % of WD patients with the
neuropsychiatric and hepatic forms of the disease, respective-
ly. No difference was identified in the age of onset between
patients with different BDNF variants, including comparisons
within and between sex groups and patients with different
dominant neurological symptoms of the disease (tremor-rigid-
ity, rigidity, tremor, dystonia; Table 3).
The BDNF Val/Val genotype occurred more frequently in
symptomatic patients than in presymptomatic patients. This
difference became even more evident when only patients
homozygous for ATP7B p.H1069Q were considered
(Table 4). In this group of patients the BDNF Val/Val geno-
type occurred more frequently in symptomatic patients than
in presymptomatic patients (logistic regression analysis p=
0.01, OR 2.71, 95 % CI 1.23–5.96).
Discussion
WD is a copper metabolism disorder that results in the
formation of unstable ceruloplasmin, which is rapidly de-
graded. The disorder results in copper accumulation in he-
patocytes (Mercer 2001). Excess copper is taken up by
extrahepatic tissues, including the brain and the cornea
limbus. Copper accumulation leads to the clinical manifes-
tation of WD.
Though classically considered to be involved in the path-
ogenesis of neurodegenerative and psychiatric disorders,
BDNF has been found outside of the central nervous system,
in muscle, heart, gonads, and in systemic circulation
(Matthews et al. 2009; Nakahashi et al. 2000). Increasing
evidence has demonstrated a function of BDNF outside the
brain, especially in metabolic health (Golden et al. 2010;
Pedersen 2009). The role of peripherally circulating BDNF in
WD is not known. The involvement of BDNF in oxidative
processes and systemic low-grade inflammatory states may at
least partly underlie BDNF’s contribution to the pathogenesis
of neurodegenerative diseases with primary hepatic patholo-
gy, although this hypothesis requires verification. Elevated
plasma BDNF levels in cardiovascular disease have been
speculated to represent a compensatory response to underly-
ing disease processes (Golden et al. 2010); a similar protective
effect may be exerted in WD by increased BDNF levels
controlled by genetic mechanisms.
To the best of our knowledge, the present study is the first
to investigate BDNF polymorphisms with regard to WD
susceptibility and the course of the disease. The distribution
of BDNF genotypes in WD patients was similar to those
described previously: 66 % for BDNF Val/Val in the current
study, as compared to 65.4 % in Alzheimer’s disease
(Ventriglia et al. 2002), 64 % in Huntington’s disease (Mai
et al. 2006), 62.9 % in cervical dystonia (Groen et al. 2012),
and 60 % in multiple sclerosis (Mirowska-Guzel et al.
2008). In the case of the BDNF C-270T polymorphism,
the C/C genotype was noted in 88.2 % of Alzheimer’s
disease patients (Kunugi et al. 2001) and 68 % of multiple
sclerosis patients (Mirowska-Guzel et al. 2008), versus 86 %
of WD patients in the current study. The distributions of
these variants are considered to be stable in diseases of
primary neurodegenerative pathology and in healthy volun-
teers. However, these previous studies were performed in
ethnically diverse populations with central nervous system
diseases with different underlying pathogenesis processes,
at least in terms of primary or secondary neurodegeneration.
Here we have determined that the BDNF Val66Met
and C-270T polymorphisms are associated with WD,
acting both independently and together. The BDNF
Val/Val genotype occurs more often in WD patients than
in controls, but the Met allele is thought to be involved
in the BDNF impairment typical of neurodegenerative
diseases. It is unclear why the BDNF Val/Val genotype
occurs more frequently in WD patients than in healthy
controls. Although the Met allele is traditionally thought
to result in decreased secretion of the peptide (Egan et
al. 2003), increased secretion of BDNF in the presence
of the Met allele was shown in an animal study (Lang
et al. 2005). The protective role of the Met allele on
working memory performance was detected in multiple
sclerosis patients (Zivadinov et al. 2007) and in
Parkinson’s disease patients (Foltynie et al. 2005), and
was evident in imaging-genetic studies of multiple
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sclerosis patients (Cerasa et al. 2010). One explanation
is that the pro-BDNF produced in the brains of Val/Val
carriers potentially interferes with the mature form of
BDNF, and may even inhibit BDNF maturation.
Furthermore, mature BDNF promotes cell survival by
activating tropomyosin-related kinase receptor B, where-
as pro-BDNF preferentially binds to the p75NTR receptor
and induces cell apoptosis (Beattie et al. 2002; Lee et
al. 2001). As we did not measure the BDNF concentra-
tion, we are unable to examine possible correlations
between either of the assessed polymorphisms and se-
rum BDNF levels.
In the present study, no difference was found in the distri-
bution of any of the investigated alleles and genotypes between
patients with two different forms of the disease at diagnosis
(hepatic or neurological). In addition, neither BDNF polymor-
phism was associated with any neurological symptoms typical
of the disease (tremor, rigidity, dystonia) or with age of disease
onset in patients with different neurological symptoms.
Considering the age of disease onset, our observations were
Table 1 Wilson’s disease patient demographics and clinical characteristics
All patients (n=414) Women (n=220) Men (n=194) Test statistics
Age at qualification for the study a 40.90±12.98 40.60±13.30 41.24±12.66 p=0.49*
Age at first symptoms a 27.18±9.38 27.51±9.82 26.83±8.92 p=0.93*
Age at diagnosis a 28.45±9.86 28.57±10.12 28.31±9.58 p=0.96*
Symptomatic, n (%) 338 (82) 174 (79) 164 (84.5) Chi2=2.04, df=1, p=0.15**
Presymptomatic, n (%) 76 (18) 46 (21) 30 (15.5)
Neuropsychiatric form, n (%) 194 (57) 84 (48) 110 (65) Chi2=12.20, df=1, p=0.0005**
Hepatic form, n (%) 145 (43) 90 (52) 54 (33)
Neurological symptoms, n
(% of all patients):
224 (54) 105 (48) 119 (61) Chi2=7.69, df=1, p=0.0055**
Discrete, n (%) 20 (9) 12 (11) 8 (7) Chi2=1.33, df=1, p=0.25**
Rigidity-tremor, n (%) 60 (27) 24 (23) 36 (31.5) Chi2=1.56, df=1, p=0.21**
Rigidity, n (%) 15 (7) 4 (4) 11 (10) Chi2=2.64, df=1, p=0.10**
Tremor, n (%) 101 (46) 53 (50) 48 (42) Chi2=2.32, df=1, p=0.13**
Dystonia, n (%) 28 (13) 12 (11) 16 (14) Chi2=0.21, df=1, p=0.65**
a Data are presented in years as mean and standard deviation
*p value from the Mann–Whitney U test comparing women and men
**Chi-squared test comparing women and men
Table 2 Frequency of BDNF Val66Met and C-270T alleles and genotypes in Wilson’s disease patients versus healthy controls
Wilson’s disease patients n=414 (%) Healthy controls n=145 (%) Test statisticsa
BDNF Val66Met
Allele frequency
Val 674 (81) 211 (73) Chi2=9.72, df=1, p=0.018, (p=0.036**)
Met 154 (19) 79 (27)
Genotype frequency
Val/Val 274 (66) 66 (45.5) Chi2=19.25, df=1, p=0.0001, (p=0.0002**)
Val/Met+Met/Met 140 (34) 79 (54.5)
BDNF C-270T
Allele frequency
C 772 (93 %) 281 (97 %) Chi2=5.25, df=1 p=0.022, (p=0.044**)
T 56 (7 %) 9 (3 %)
Genotype frequency
C/C 358 (86 %) 136 (94 %) Chi2=5.60, df=1 p=0.018, (p=0.036**)
C/T 56 (14 %) 9 (6 %)
a Chi-squared test
b Bonferroni correction
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similar to those previously made in patients with cervical
dystonia (Groen et al. 2012); no associations were noted be-
tween the BDNF Val66Met polymorphism and age of onset,
but a higher frequency of bilateral postural arm tremor was
observed in patients with the BDNF Val/Val genotype. In
contrast, we did not uncover any association between the
BDNF Val66Met and C-270T polymorphisms and tremor in
WD. Although BDNF is known to be widely distributed
in the mammalian brain, significant differences may
exist in its localization and distribution, especially in
neurodegenerative disorders. In Huntington’s disease,
reduced expression of BDNF occurred in the putamen
and caudate compared to controls, but expression was
preserved in the temporal cortex, parietal cortex, and hippo-
campus (Ferrer et al. 2000). No such studies have been
performed with WD patients, and thus we cannot be certain
whether any differences exist in BDNF expression in various
brain structures in WD patients.
An interesting finding is the significant difference in the
distribution of BDNF Val/Val between symptomatic and
presymptomatic WD patients. The more evident difference
in ATP7B p.H0169Q homozygotes can be explained by the
homogeneity of our population of WD patients. The BDNF
Val allele may exert a protective role, but this hypothesis
requires verification by long-term observation of our group
of patients.
Table 3 Distribution of BDNF Val66Met and C-270T genotypes in Polish patients with Wilson’s disease with respect to the dominant neurological
form of the disease
Wilson’s disease patients BDNF BDNF p-value BDNF BDNF p-value
Val/Val Val/Met + Met/Met C/C C/T
(n=274) (n=140) (n=358) (n=56)
Age at onset a 26.65±9.51 26.79±9.83 0.77* 26.85±9.76 25.83±8.67 0.57*
Age at diagnosis a 28.53±9.51 28.28±10.58 0.68* 28.47±10.07 28.30±8.56 0.93*
Dominant neurological form, n (%):
Rigidity-tremor (n=60) 40 (67) 20 (33) 0.93** 48 (80) 12 (20) 0.11**
Rigidity (n=15) 12 (80) 3 (20) 0.25** 13 (87) 2 (13) 0.98**
Tremor (n=101) 69 (68) 32 (32) 0.60** 90 (89) 11 (11) 0.37**
Dystonia (n=28) 20 (71) 8 (29) 0.54** 24 (86) 4 (14) 0.90**
a Data are presented in years as mean and standard deviation
*Mann–Whitney U test for age comparisons between carriers of different BDNF Val66Met and C-270T genotypes
**Chi-squared test for distribution of WD forms between different BDNF Val66Met and C-270T genotypes
Table 4 Distribution of BDNF Val66Met and C-270T genotypes in symptomatic and presymptomatic Wilson’s disease patients harboring the
ATP7B 1069 HQ/HQ genotype
Symptomatic n=153 (%) Presymptomatic n=34 (%) Test statistics*
BDNF Val66Met
Allele frequency
Val 262 (86) 51 (75) Chi2=4.60, df=1, p=0.032
Met 44 (14) 17 (25)
Genotype frequency
Val/Val 115 (75) 18 (53) Chi2=6.69, df=1, p=0.0097
Val/Met+Met/Met 38 (26) 16 (47)
BDNF C-270T
Allele frequency
C 284 (93) 64 (94) Chi2=0.01, df=1, p=0.9046**
T 22 (7) 4 (6)
Genotype frequency
C/C 131 (86) 30 (88) Chi2=0.02, df=1, p=0.9009**
C/T 22 (14) 4 (12)
*Chi-squared test
**Yates correction for fewer than five samples
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In conclusion, the results of the present study suggest that
genetically determined BDNF functions may be related to the
occurrence of WD but not with its course or symptomatology.
However, large variations in the age of onset and clinical
manifestation of WD make this hypothesis difficult to inves-
tigate. The other major limitation of the current study is due to
this study’s ability to detect only the association of two par-
ticular BDNF polymorphisms withWD, similar to many other
studies; however, these relationships are difficult to explain on
a molecular level. We cannot exclude the possibility that the
observed effect is due to another gene located near BDNF on
the chromosome, as pathogenic mutations in a neighboring
gene causing or modifying WD could be overlooked by this
study design. To validate the present results, further studies are
needed to elucidate the role andmechanism ofBDNF action in
WD susceptibility and disease course.
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